Neoadjuvant camrelizumab and apatinib combined with chemotherapy versus chemotherapy alone for locally advanced gastric cancer: a multicenter randomized phase 2 trial.

Nat Commun · 2024 · PMC10762218 · PMID 38167806

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Compared with the SAP group, the CA-SAP group showed a trend toward a higher MPR rate in patients with MSI-H (66.7% [2 of 3 patients with CA-SAP] versus 0.0% [0 of 3 patients with SAP]) than in those with microsatellite stability (MSS; 32.6% [15 of 46 patients with CA-SAP] versus 19.1% [9 of 47 patients with SAP]).

also in 53,322 other papers

did not reach statistical significanceno p-value reported

However, this interaction did not reach statistical significance ( P for interactio n = 0.227).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.